NGM BIOPHARMACEUTICALS INC Quarterly Operating Income (Loss) in USD from Q1 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ngm Biopharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q4 2023.
  • Ngm Biopharmaceuticals Inc Operating Income (Loss) for the quarter ending December 31, 2023 was -$29.7M, a 22.5% increase year-over-year.
  • Ngm Biopharmaceuticals Inc Operating Income (Loss) for the twelve months ending December 31, 2023 was -$151M, a 8.89% increase year-over-year.
  • Ngm Biopharmaceuticals Inc annual Operating Income (Loss) for 2023 was -$151M, a 8.89% increase from 2022.
  • Ngm Biopharmaceuticals Inc annual Operating Income (Loss) for 2022 was -$166M, a 37.7% decline from 2021.
  • Ngm Biopharmaceuticals Inc annual Operating Income (Loss) for 2021 was -$121M, a 16.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 -$151M -$29.7M +$8.63M +22.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$160M -$31M +$17.3M +35.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$177M -$40.6M +$6.49M +13.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 -$184M -$50.2M -$17.6M -54.1% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-04
Q4 2022 -$166M -$38.3M -$11.1M -40.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$155M -$48.3M -$19.3M -66.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$136M -$47.1M -$10.4M -28.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$125M -$32.6M -$4.74M -17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$121M -$27.2M +$449K +1.62% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-11
Q3 2021 -$121M -$29M +$951K +3.18% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$122M -$36.6M -$11.1M -43.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$111M -$27.8M -$7.18M -34.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$104M -$27.7M -$10.4M -60% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$93.5M -$30M -$17M -130% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$76.5M -$25.5M -$15.8M -163% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$60.7M -$20.7M -$11.3M -121% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$49.3M -$17.3M -$30.4M -232% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-17
Q3 2019 -$19M -$13M -$4.53M -53.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$14.5M -$9.71M -$5.52M -132% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$8.94M -$9.34M -$4.63M -98.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 -$4.31M $13.1M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-17
Q3 2018 -$8.47M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-17
Q2 2018 -$4.19M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-17
Q1 2018 -$4.72M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.